Compass Wealth Management LLC Invests $2.04 Million in Regeneron Pharmaceuticals, Inc. $REGN

Compass Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 3,634 shares of the biopharmaceutical company’s stock, valued at approximately $2,043,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dodge & Cox grew its stake in Regeneron Pharmaceuticals by 64.6% in the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after purchasing an additional 1,502,198 shares in the last quarter. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $628,151,000. Acadian Asset Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 234.7% in the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after buying an additional 326,583 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in shares of Regeneron Pharmaceuticals by 18.6% in the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after buying an additional 305,089 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Regeneron Pharmaceuticals by 26.5% during the second quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after buying an additional 225,078 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on REGN shares. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Citigroup upped their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. HSBC upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Scotiabank upped their price objective on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research note on Monday, November 24th. Finally, Wells Fargo & Company raised their price objective on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals Trading Down 1.2%

Shares of REGN stock opened at $782.38 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a market capitalization of $82.71 billion, a PE ratio of 18.83, a price-to-earnings-growth ratio of 2.13 and a beta of 0.40. The firm has a 50 day moving average price of $768.21 and a two-hundred day moving average price of $671.68. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the firm posted $12.07 EPS. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a dividend of $0.94 per share. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 8.47%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director owned 17,803 shares of the company’s stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,636 shares of company stock worth $2,862,920 in the last quarter. 7.02% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.